> For Research Use Only. MOTS-c is not approved by the FDA or any regulatory agency for human therapeutic use. This article is intended for licensed researchers, educators, and scientific professionals. It does not constitute medical advice or encourage self-administration.
---
Introduction
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 12-amino-acid peptide encoded not by the nuclear genome but by a small open reading frame within mitochondrial DNA — specifically the 12S ribosomal RNA gene. Its discovery in 2015 by Lee and colleagues fundamentally changed how scientists understand mitochondria: rather than passive energy factories, mitochondria are now recognized as endocrine-like organelles capable of secreting bioactive peptides that communicate with the rest of the cell and even the nucleus.
The sequence of MOTS-c — MRWQEMGYIFY — is conserved across vertebrates, a hallmark of evolutionary importance. Unlike most mitochondrial gene products, MOTS-c is not part of the electron transport chain; it is a signaling molecule that exits the mitochondrial matrix and translocates to the nucleus under conditions of metabolic stress.
What makes MOTS-c scientifically compelling is its role as a potential exercise mimetic. Administration of MOTS-c in preclinical models produces metabolic benefits that closely resemble those induced by physical exercise — improved insulin sensitivity, reduced adiposity, and enhanced mitochondrial biogenesis — without the exercise itself. This positions MOTS-c at the intersection of aging biology, metabolic disease, and exercise physiology, making it one of the most actively studied mitochondrial-derived peptides (MDPs) in current research.
---
Mechanism of Action
MOTS-c operates through a multi-layered signaling cascade. Its primary molecular target is the folate cycle within mitochondria: MOTS-c inhibits the folate cycle enzyme MTHFD2, leading to accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), an endogenous AMP-activated protein kinase (AMPK) activator.
AMPK activation is the central downstream effector. AMPK serves as the cell's master energy sensor — when activated, it promotes:
- •Glucose uptake via GLUT4 translocation to the plasma membrane
- •Fatty acid oxidation by inhibiting ACC (acetyl-CoA carboxylase)
- •Mitochondrial biogenesis via PGC-1α upregulation
- •Inhibition of mTORC1, reducing anabolic processes that consume energy
What distinguishes MOTS-c from other AMPK activators is its capacity for nuclear translocation. Under cellular stress — including oxidative stress, nutrient deprivation, and exercise — MOTS-c moves from the cytoplasm into the nucleus, where it interacts with ARE (antioxidant response element) binding proteins and modulates nuclear gene expression. Kim et al. (2018) demonstrated that nuclear MOTS-c directly binds to stress-responsive promoters, including those controlling antioxidant enzymes and metabolic regulators, acting as a retrograde signal from the mitochondria to the nucleus.
This nuclear activity is distinct from cytoplasmic AMPK signaling and may explain why the metabolic effects of MOTS-c persist beyond what would be expected from AMPK activation alone. The peptide functions as a genuine mitochondria-to-nucleus messenger — a concept once considered impossible given the separation between these compartments.
In skeletal muscle, MOTS-c promotes glucose utilization through both AMPK-dependent and AMPK-independent mechanisms, with downstream activation of the TERC/LKB1/AMPK axis contributing to insulin sensitization in insulin-resistant states.
---
Key Research Findings
1. Discovery: Metabolic Homeostasis and Obesity Reduction (Lee et al., 2015)
The foundational MOTS-c study demonstrated that systemic administration of synthetic MOTS-c in diet-induced obese mice reduced body weight, improved insulin sensitivity, and restored metabolic flexibility. MOTS-c-treated mice showed enhanced glucose uptake in skeletal muscle without increasing lean mass — consistent with an exercise-like effect on fuel utilization. The authors proposed that MOTS-c is a hormetic signal released by mitochondria in response to metabolic stress, priming the body for increased energy demands. This paper established MOTS-c as a bona fide mitohormone. [PMID: 25738459]
2. Nuclear Translocation and Gene Regulation (Kim & Son, 2018)
This study provided the mechanistic basis for MOTS-c's gene-regulatory activity. Using fluorescence tracking and chromatin immunoprecipitation, researchers showed that MOTS-c translocates to the nucleus during oxidative and metabolic stress. In the nucleus, MOTS-c interacts with ARE-containing promoters and amplifies the expression of antioxidant response genes — Nrf2 targets among them. The finding that a mitochondrially encoded peptide can directly regulate nuclear transcription represents a paradigm shift in understanding retrograde mitochondria-nucleus communication. [PMID: 29983246]
3. Aging, Stem Cell Function, and Regeneration (Yu & Kim, 2021)
In human placenta-derived mesenchymal stem cells from aged donors, MOTS-c treatment restored proliferative capacity, reduced markers of cellular senescence, and improved mitochondrial membrane potential. The study found that aged cells have lower endogenous MOTS-c levels — a finding mirroring circulating MOTS-c data showing that serum levels decline with age in humans. Supplementation with exogenous MOTS-c partially reversed these age-related deficits, raising interest in MOTS-c as a geroscience target. [PMID: 33639272]
4. MOTS-c in Energy Metabolism: Systems View (Merry & Chan, 2020)
This review synthesized emerging data on MOTS-c alongside other MDPs including humanin and SHLP2, placing MOTS-c's AMPK-folate cycle axis into a broader framework of mitochondrial endocrinology. The authors highlighted that MDPs are released into circulation in response to exercise and metabolic stress, acting as systemic signals that coordinate whole-body energy homeostasis — bridging organ systems including liver, muscle, adipose, and brain. [PMID: 32776825]
5. Aging and Age-Related Disease Context (Kim & Miller, 2021)
A comprehensive review examining how circulating MOTS-c levels correlate with metabolic health across the lifespan, noting inverse relationships with obesity, insulin resistance, and type 2 diabetes. The authors discuss MOTS-c as a potential biomarker of mitochondrial health and a candidate therapeutic target for metabolic syndrome and age-associated decline, while noting the need for human clinical trial data. [PMID: 32910336]
---
Research Applications
MOTS-c is studied across several research domains:
Metabolic Disease Models: Rodent models of type 2 diabetes, diet-induced obesity, and insulin resistance. MOTS-c is administered via subcutaneous injection or intraperitoneal injection at doses of 5–15 mg/kg/day in rodents; dosing regimens in cell culture typically use 1–10 µM concentrations.
Aging and Longevity Biology: Models of cellular senescence, aged tissue function, and organismal lifespan. MOTS-c is evaluated alongside caloric restriction and exercise mimetic interventions for its ability to maintain healthspan.
Exercise Science: As a putative exercise-induced hormone (exerkine), MOTS-c is measured in response to acute and chronic exercise in human plasma, with interest in its role as a mediator of exercise benefits in sedentary or mobility-limited populations.
Neurological Models: Emerging data suggest MOTS-c may exert neuroprotective effects, including in models of oxidative stress and neurodegeneration — though this area remains at early-stage investigation.
Common model organisms: C57BL/6 mice, ob/ob mice, Sprague-Dawley rats, human primary cell cultures (skeletal muscle cells, adipocytes, MSCs).
---
Safety & Limitations
No human clinical trials of synthetic MOTS-c have been completed as of 2026. All mechanistic data derive from cell-based studies and rodent models, creating an inherent translational gap. Key limitations include:
- •Route and bioavailability: As a peptide, MOTS-c is subject to proteolytic degradation following subcutaneous injection; modifications to improve stability are under research.
- •Dose extrapolation: Rodent doses (5–15 mg/kg) do not directly translate to human equivalents without allometric scaling and PK studies.
- •Nuclear translocation mechanism: While documented in vitro and in vivo in rodents, the conditions governing nuclear entry in human tissues are incompletely characterized.
- •Long-term effects: No chronic safety data exist for exogenous MOTS-c administration.
MOTS-c should be handled under standard peptide research protocols, stored at –20°C or –80°C, and used only in properly approved research settings.
---
Sourcing on Peptides.SO
Researchers can compare verified MOTS-c suppliers on Peptides.SO's MOTS-c peptide page, which aggregates listings from 138+ suppliers as of 2026. The platform's price-comparison tools allow side-by-side evaluation of cost per milligram, purity certificates (HPLC/MS), and vendor reputation scores — enabling research procurement teams to identify quality-verified sources quickly.
Related research profiles on Peptides.SO: SS-31 Research Profile, Humanin Research Profile.
---
References
1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443–454. PMID: 25738459. DOI: 10.1016/j.cmet.2015.02.009
2. Kim KH, Son JM, Benayoun BA, Lee C. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metab. 2018;28(3):516–524.e7. PMID: 29983246. DOI: 10.1016/j.cmet.2018.06.023
3. Yu WD, Kim YJ, Lee S, et al. The mitochondrial-derived peptide MOTS-c promotes homeostasis in aged human placenta-derived mesenchymal stem cells. Stem Cell Res Ther. 2021;12(1):480. PMID: 33639272. DOI: 10.1186/s13287-021-02510-5
4. Merry TL, Chan A, Doig J, et al. Mitochondrial-derived peptides in energy metabolism. Am J Physiol Endocrinol Metab. 2020;319(4):E659–E666. PMID: 32776825. DOI: 10.1152/ajpendo.00249.2020
5. Kim SJ, Miller B, Harber M, et al. Mitochondrial-derived peptides in aging and age-related diseases. GeroScience. 2021;43(2):1113–1129. PMID: 32910336. DOI: 10.1007/s11357-020-00279-2